253 related articles for article (PubMed ID: 35739510)
21. Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.
Li L; Chen X; Hao L; Chen Q; Liu H; Zhou Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32662515
[TBL] [Abstract][Full Text] [Related]
22. Bioinformatic identification of renal cell carcinoma microenvironment-associated biomarkers with therapeutic and prognostic value.
Zeng Q; Zhang W; Li X; Lai J; Li Z
Life Sci; 2020 Feb; 243():117273. PubMed ID: 31926244
[TBL] [Abstract][Full Text] [Related]
23. Identification of a Somatic Mutation-Derived Long Non-Coding RNA Signatures of Genomic Instability in Renal Cell Carcinoma.
Fang X; Liu X; Lu L; Liu G
Front Oncol; 2021; 11():728181. PubMed ID: 34676164
[TBL] [Abstract][Full Text] [Related]
24. The roles of ferroptosis regulatory gene SLC7A11 in renal cell carcinoma: A multi-omics study.
Xu F; Guan Y; Xue L; Zhang P; Li M; Gao M; Chong T
Cancer Med; 2021 Dec; 10(24):9078-9096. PubMed ID: 34761566
[TBL] [Abstract][Full Text] [Related]
25. Exploration of the immune-related signature and immune infiltration analysis for breast ductal and lobular carcinoma.
Zhang B; Wang Q; Fu C; Jiang C; Ma S
Ann Transl Med; 2019 Dec; 7(23):730. PubMed ID: 32042746
[TBL] [Abstract][Full Text] [Related]
26. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
[TBL] [Abstract][Full Text] [Related]
27. DYSF expression in clear cell renal cell carcinoma: A retrospective study of 2 independent cohorts.
Ha M; Jeong H; Roh JS; Lee B; Han ME; Oh SO; Sohn DH; Kim YH
Urol Oncol; 2019 Oct; 37(10):735-741. PubMed ID: 31377166
[TBL] [Abstract][Full Text] [Related]
28. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
[TBL] [Abstract][Full Text] [Related]
29. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
30. Integrative bioinformatics analysis of a prognostic index and immunotherapeutic targets in renal cell carcinoma.
Tao H; Li Z; Mei Y; Li X; Lou H; Dong L; Zhou L
Int Immunopharmacol; 2020 Oct; 87():106832. PubMed ID: 32738597
[TBL] [Abstract][Full Text] [Related]
31. Identifying Hypoxia Characteristics to Stratify Prognosis and Assess the Tumor Immune Microenvironment in Renal Cell Carcinoma.
Zhang Z; Li Q; Wang F; Ma B; Meng Y; Zhang Q
Front Genet; 2021; 12():606816. PubMed ID: 34194463
[No Abstract] [Full Text] [Related]
32. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma.
Tripathi A; Lin E; Xie W; Flaifel A; Steinharter JA; Stern Gatof EN; Bouchard G; Fleischer JH; Martinez-Chanza N; Gray C; Mantia C; Thompson L; Wei XX; Giannakis M; McGregor BA; Choueiri TK; Agarwal N; McDermott DF; Signoretti S; Harshman LC
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177176
[TBL] [Abstract][Full Text] [Related]
33. A five-gene signature may predict sunitinib sensitivity and serve as prognostic biomarkers for renal cell carcinoma.
Chen YL; Ge GJ; Qi C; Wang H; Wang HL; Li LY; Li GH; Xia LQ
J Cell Physiol; 2018 Oct; 233(10):6649-6660. PubMed ID: 29327492
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm.
Luo J; Xie Y; Zheng Y; Wang C; Qi F; Hu J; Xu Y
Cancer Med; 2020 Jun; 9(12):4310-4323. PubMed ID: 32311223
[TBL] [Abstract][Full Text] [Related]
35. Identification of Survival Risk and Immune-Related Characteristics of Kidney Renal Clear Cell Carcinoma.
Wu X; Liang Y; Chen X; Long X; Xu W; Liu L; Wang B; Zou X
J Immunol Res; 2022; 2022():6149369. PubMed ID: 35832648
[TBL] [Abstract][Full Text] [Related]
36. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
Chen J; Chen X; Li T; Wang L; Lin G
Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
[TBL] [Abstract][Full Text] [Related]
37. A novel immune-related prognostic index for predicting breast cancer overall survival.
Yu X; Guo J; Zhou Q; Huang W; Xu C; Long X
Breast Cancer; 2021 Mar; 28(2):434-447. PubMed ID: 33146847
[TBL] [Abstract][Full Text] [Related]
38. Immunogenomic Analyses of the Prognostic Predictive Model for Patients With Renal Cancer.
Feng T; Zhao J; Wei D; Guo P; Yang X; Li Q; Fang Z; Wei Z; Li M; Jiang Y; Luo Y
Front Immunol; 2021; 12():762120. PubMed ID: 34712244
[TBL] [Abstract][Full Text] [Related]
39. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
40. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
